Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT followed by novel AR inhibitor plus PD-1 inhibitor in mCRPC
ChiCTR2600116595Phase 3Recruiting
- Sponsor
- Beijing Hospital
- Start
- Jan 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of testosterone, ravelutamide and camrelizumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Beijing Hospital. Primary endpoint: PSA remission rate after end of treatment. Started Jan 2026; status: recruiting.
02
Drugs
testosteroneravelutamidecamrelizumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR2600116595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116595.